- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
U.S. Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
474
0 new
Companies with a Value score of at least 3, ordered by Value score
474 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
AVTR | US$17.35 | -5.7% | -27.9% | US$12.2b | US$24.85 | PE16.6x | E-2.9% | n/a | ||
VTRS | US$10.86 | 2.4% | -18.0% | US$12.9b | US$13.20 | PS0.9x | E52.4% | 4.4% | ||
AMPH | US$30.75 | -4.5% | -41.4% | US$1.5b | US$44.40 | PE9.4x | E5.6% | n/a | ||
MRK | US$83.29 | -3.8% | -34.6% | US$210.0b | US$115.42 | PE12.3x | E7.6% | 3.9% | ||
EXAS | US$49.63 | -1.4% | -21.6% | US$9.2b | US$72.19 | PS3.4x | E59.1% | n/a | ||
KNSA | US$19.55 | -0.8% | -1.9% | US$1.4b | US$36.00 | PS3.7x | E49.4% | n/a | ||
JAZZ | US$135.39 | 4.2% | 7.1% | US$8.1b | US$184.37 | PE17.7x | E9.7% | n/a | ||
IQV | US$193.15 | -3.9% | -17.7% | US$34.1b | US$247.60 | PE24.8x | E14.4% | 0% | ||
COLL | US$29.71 | -5.9% | -7.4% | US$956.5m | US$42.80 | PE10.8x | E26.4% | n/a | ||
TEVA | US$16.57 | -0.1% | 26.8% | US$18.4b | US$23.79 | PS1.1x | E66.6% | 0% | ||
BIO | US$283.21 | -10.0% | -17.6% | US$7.9b | US$372.83 | PS3.1x | E74.6% | n/a | ||
ANIP | US$58.73 | -1.9% | 0.6% | US$1.2b | US$78.67 | PS2.1x | E59.0% | n/a | ||
ICLR | US$188.65 | 0.7% | -33.5% | US$15.4b | US$256.82 | PE20.8x | E10.6% | n/a | ||
FENC | US$6.74 | 3.7% | -23.6% | US$183.5m | US$12.60 | PS3.8x | E48.6% | n/a | ||
INDV | US$10.83 | 7.4% | -35.0% | US$1.1b | US$16.53 | PS1.1x | E42.6% | 0% | ||
PFE | US$25.56 | 0.1% | -7.4% | US$144.7b | US$31.18 | PE18.1x | E3.6% | 6.7% | ||
AMRX | US$7.79 | -2.1% | 34.8% | US$2.4b | US$10.50 | PS0.9x | E154.7% | 0% | ||
FTRE | US$15.22 | 1.0% | -57.0% | US$1.3b | US$22.20 | PS0.5x | E60.9% | n/a | ||
PTGX | US$37.75 | 2.1% | 38.6% | US$2.3b | US$58.40 | PE13.2x | E-7.2% | n/a | ||
TCNN.F | US$4.27 | -8.0% | -50.8% | US$1.2b | US$15.36 | PS0.7x | E56.5% | n/a | ||
ERFS.F | US$53.23 | -0.4% | -14.0% | US$9.3b | US$63.00 | PE26.1x | E18.5% | 1.2% | ||
CRLB.F | US$0.88 | -3.0% | -49.4% | US$587.4m | US$2.68 | PS0.4x | E57.0% | n/a | ||
RCEL | US$10.34 | 18.9% | -41.2% | US$278.6m | US$16.82 | PS4.2x | E53.4% | n/a | ||
BAYZ.F | US$22.56 | 5.2% | -27.3% | US$21.3b | US$28.67 | PS0.5x | E44.9% | 0.5% |